Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy DOI

Haojie Shang,

Xia Ding, Rui Geng

и другие.

ACS Nano, Год журнала: 2025, Номер unknown

Опубликована: Май 17, 2025

Bladder cancer is a common malignant tumor of the urinary system and associated with high morbidity, recurrence, mortality rates. Immunotherapy immune checkpoint inhibitors has shown great therapeutic outcomes safety in bladder cancer. Immune have also been approved as first- second-line drugs for treatment locally advanced or metastatic However, immunotherapy low response drug assistance immunotherapy, which can be ascribed to insufficient antigen presentation, immunosuppressive cell accumulation, T lymphocyte exhaustion microenvironment. To overcome disadvantages we prepared resiquimod (R848)/photothermal agent (DTPA)-loaded lipid nanoparticle (R848/DTPA@DSPE-PEG NP), good photothermal conversion efficiency, biosafety, biocompatibility. R848/DTPA@DSPE-PEG NPs laser irradiation (635 nm) damage MB49 cells induce immunogenic death vitro, could trigger an response. Meanwhile, promote M1-like macrophage polarization dendritic maturation vitro. Moreover, 635 nm suppress subcutaneous orthotopic growth activate response, polarization, enhance CD8+ infiltration, reduce M2-like tumors. Bioinformatics analysis found that immune-related gene overexpression signaling pathways. Combined PD-1 antibody significantly antitumor effects, reprogram microenvironment, prolong survival time.

Язык: Английский

Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy DOI

Haojie Shang,

Xia Ding, Rui Geng

и другие.

ACS Nano, Год журнала: 2025, Номер unknown

Опубликована: Май 17, 2025

Bladder cancer is a common malignant tumor of the urinary system and associated with high morbidity, recurrence, mortality rates. Immunotherapy immune checkpoint inhibitors has shown great therapeutic outcomes safety in bladder cancer. Immune have also been approved as first- second-line drugs for treatment locally advanced or metastatic However, immunotherapy low response drug assistance immunotherapy, which can be ascribed to insufficient antigen presentation, immunosuppressive cell accumulation, T lymphocyte exhaustion microenvironment. To overcome disadvantages we prepared resiquimod (R848)/photothermal agent (DTPA)-loaded lipid nanoparticle (R848/DTPA@DSPE-PEG NP), good photothermal conversion efficiency, biosafety, biocompatibility. R848/DTPA@DSPE-PEG NPs laser irradiation (635 nm) damage MB49 cells induce immunogenic death vitro, could trigger an response. Meanwhile, promote M1-like macrophage polarization dendritic maturation vitro. Moreover, 635 nm suppress subcutaneous orthotopic growth activate response, polarization, enhance CD8+ infiltration, reduce M2-like tumors. Bioinformatics analysis found that immune-related gene overexpression signaling pathways. Combined PD-1 antibody significantly antitumor effects, reprogram microenvironment, prolong survival time.

Язык: Английский

Процитировано

0